Belmont, CA, United States of America

Ehdieh Khaledian

USPTO Granted Patents = 1 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Ehdieh Khaledian: Innovator in Multi-Omic Assessment

Introduction

Ehdieh Khaledian is an accomplished inventor based in Belmont, California, who has made significant contributions to the field of biomedical research. His innovative work is primarily focused on developing methods to assess diseases using multi-omic approaches, particularly in the context of cancer.

Latest Patents

Khaledian holds one patent titled "Multi-omic assessment using proteins and nucleic acids." This groundbreaking patent describes methods for assessing diseases, including cancer, by integrating data from various omics disciplines such as proteomics, transcriptomics, genomics, lipidomics, and metabolomics. Additionally, the patent outlines methods for screening biological samples to determine whether nodules, masses, or cysts are cancerous.

Career Highlights

Ehdieh Khaledian is currently associated with Prognomiq, Inc., where he applies his expertise to advance the company's mission in disease assessment technologies. His role has allowed him to pioneer innovative solutions that improve diagnostic accuracy and patient outcomes in cancer treatment.

Collaborations

Khaledian works alongside his colleague Philip Ma, contributing to the collective efforts at Prognomiq, Inc. Their collaboration aims to expand the capabilities of multi-omic assessment methodologies, further validating the clinical applications of their research.

Conclusion

In summary, Ehdieh Khaledian stands out as an innovative inventor in the realm of multi-omic assessments, particularly for cancer diagnostics. With his patent and ongoing contributions to Prognomiq, Inc., he continues to shape the future of biomedical research and diagnostics, paving the way for more accurate and effective disease screening methods.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…